Research & Development



  陽陵邑外的戰斗依舊進行的如火如荼……霍光臉色陰冷,一次次的揮動了手中的旗子,于是,投石機就一次又一次的將石彈送進了已經快成廢墟的陽陵邑。   天下太大了,大漢國人口太多了,大漢國的權力也太繁雜了,不是一個人可以管理的過來的。插姐姐   人參只能吊命,無法讓病人康復。日妹妹   曹襄嘆口氣道︰“你還是指望今天贏點錢比較靠譜。”   為了這個理想,霍光原本準備將自己有限的生命全部投入進去。妹妹影院   他依舊離不開皇帝這個名號的禁錮,傳說中的《罪己詔》已經修改了三稿,皇帝依舊不滿意,雲哲與霍光,梁凱,桑弘羊,汲黯,梁贊六人還留在皇宮中,為皇帝撰寫能讓他滿意的《罪己詔》。

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo